RIS Asian Biotechnology and Development Review Research and Information System Vol. 16 No.3, pp 3-23 for Developing Countries © 2014, RIS. Divergence, Convergence, and Innovation: East-West Bioscience in an Anxious Age William Hoffman* and Leo Furcht** Abstract:  If  current  economic  growth  trends  persist,  the  “Great  Divergence”   between  Western  Europe  and  East  and  South  Asia  in  per  capita  income  that   commenced  two  hundred  years  ago  will  close  sometime  this  century.  Key  to   the  closing  will  be  greater  accessibility  to  technology  and  higher  education  in   East  and  South  Asia  and  the  relentless  diffusion  of  knowledge  including  in  the   biosciences.  Advances  in  the  biosciences  are  poised  to  contribute  in  a  major   way  to  Thomas  Malthus’s  four  necessities  of  human  life  –  food,  fiber,  fuel,   and  building  materials  –  as  well  as  to  human  and  animal  health,  biodiversity   conservation,  and  environmental  remediation  and  sustainability.  Powerful  new   biological  technologies  like  genomics  and  synthetic  biology  are  just  beginning   to  be  applied  in  ways  that  can  sever  the  link  between  economic  growth  and   carbon  pollution.  Precise  genomic  editing  of  cereal  grains  could  equip  rice,   wheat,  and  maize  with  nitrogen  fixation  capabilities,  thus  reducing  the  need   for  synthetic  fertilisers  with  their  environmental  and  atmospheric  costs.  East   and  South  Asia,  facing  major  food  production  challenges,  ecological  limits,   pollution  from  fertiliser  use,  and  drought  from  climate  change,  may  take  the   lead  over  the  West  in  adopting  innovative  food  crop  technologies.   Keywords:    bioscience,  innovation,  energy,  ecosystems,  genomics,  GM  crops     Two  centuries  ago  Britain  and  Western  Europe  began  to  leave  the  rest  of   the  Eurasian  continental  landmass  behind  in  per  capita  income  (Maddison   2006).    Historian  Kenneth  Pomeranz  called  the  phenomenon  that  separated   Europe  from  China  economically  the  “Great  Divergence”  (Pomeranz   2000).  He  borrowed  the  term  from  political  scientist  and  historian  Samuel   *     Department  of  Laboratory  Medicine  and  Pathology,  University  of  Minnesota  Medical  School.   Email:  [email protected] **    Department  of  Laboratory  Medicine  and  Pathology,  University  of  Minnesota  Medical  School. 4 Asian Biotechnology and Development Review P.  Huntington  who  used  it  to  illuminate  how  the  Western  world  overcame   pre-­modern  economic  growth  constraints  and  surged  ahead  of  the  East   beginning  in  the  nineteenth  century.     Some  scholars,  Pomeranz  included,  attribute  the  divergence  to   colonialism,  intercontinental  trade,  and  especially  energy  production  from   the  burning  of  Carboniferous  biomass  in  the  form  of  coal,  which  was   plentiful  in  England’s  West  Midlands  where  the  Industrial  Revolution   began.  Pomeranz  reminds  us  that  technological  innovation  and  economic   development  occur  in  an  ecological  context.  He  takes  into  account  the   exploitation  of  land-­based  biosystems  for  food,  fiber,  fuel,  and  building   materials  production  –  English  economist  Thomas  Malthus’s  four   necessities  of  life,  which  were  in  competition  with  each  other  for  land  –   and  the  ecological  constraints  to  economic  growth  such  exploitation  posed.   Colonial  resources  and  conveniently  located  coal  served  to  alleviate  these   ecological  constraints  in  Britain  and  set  the  country  on  a  path  of  scientific   and  technological  advance  with  supportive  social  and  political  institutions   for  entrepreneurs.     Environmental  history  is  one  of  the  fastest  growing  sub-­disciplines  of   the  field  (Burke  2009).1  It  is  destined  to  become  more  important  with  the   growing  environmental  consequences  from  massive  extraction  and  burning   of  fossil  fuels,  the  damming  of  rivers,  deforestation,  and  the  production  and   use  of  nitrogen-­based  fertilizers  and  cement.    “If  the  eighteenth  century   pushed  the  limits  of  the  biological  old  regime,  the  nineteenth  century  and   especially  the  twentieth  century  shattered  them”  (Pomeranz  2009).2  The   biological  new  regime,  as  Pomeranz  describes  it,  is  distinguished  by  half  of   the  growth  in  the  human  population  occurring  in  the  past  thirty  years,  half   of  all  net  water  withdrawals  in  the  past  fifty  years,  a  fifteen-­fold  increase  in   annual  energy  consumption  since  1900,  and  unprecedented  environmental   degradation  and  adverse  impacts.   Twenty-­first  century  history,  when  it  is  written,  will  further  entwine  the   economic  and  ecological  storylines  of  the  human  experience.    It  will  also   provide  a  bookend  for  the  “Great  Divergence”  of  the  previous  two  centuries,   given  current  global  trends  in  economic  growth,  advanced  education,  and   technological  innovation  (Dervis  2012).  The  world  economy’s  center  of   gravity  has  been  migrating  eastward  for  three  decades,  reflecting  rapid   growth  in  incomes  of  the  vast  populations  of  China,  India,  and  the  rest  of Divergence, Convergence, and Innovation: East-West Bioscience in an Anxious Age 5 East  and  South  Asia  (Quah  2011)  and  producing  anxiety  in  the  West  over   its  eroding  economic  leadership  since  1980.  The  gradual  convergence  in   East-­West  per  capita  income,  uneven  as  it  is,3  will  continue  to  be  influenced   by  trade,  capital  investment  in  the  East,  the  rapidly  emerging  Asian  middle   class,  and  the  East’s  greater  accessibility  to  higher  education  and  technology   than  ever  before.  Technological  convergence  among  nations  and  between   different  parts  of  the  world  may  be  abetted  by  free  trade  and  foreign  direct   investment,  but  it  is  fundamentally  a  process  of  the  diffusion  and  sharing   of  knowledge  –  “the  public  good  par  excellence”  (Piketty  2014). Environmentally  sustainable  economic  growth  will  require  putting   knowledge  of  life  code,  cellular  processes,  biosynthesis,  and  biological   regeneration  to  practical  use.  The  biosciences  are  in  the  midst  of  a   convergence  of  their  own  –  with  information  technology,  nanotechnology,   microelectronics,  materials,  artificial  intelligence,  robotics,  architecture,  and   design.  The  field  is  poised  to  contribute  in  a  major  way  to  Malthus’s  four   necessities  of  human  life  –  food,  fiber,  fuel,  and  building  materials  (bio-­ based  construction  materials).  That  will  occur  on  top  of  the  contribution   of  the  genomic  science,  molecular  and  synthetic  biology,  regenerative   medicine  and  other  biological  technologies  make  to  human  and  animal   health,  biodiversity  conservation,  and  environmental  remediation  and   resilience  (OECD  2009;  Chaturvedi  and  Srinivas  2014;  Hoffman  and  Furcht   2014;  Hoffman  2014).     Technological  innovation  is  responsible  for  more  than  half  of  the   growth  in  advanced  economies  by  most  accounts.4  Though  biotechnology   was  pioneered  in  the  West,  today  it  is  a  global  enterprise,  with  major  hubs   in  China,  Hong  Kong,  India,  Japan,  Singapore,  South  Korea,  and  Taiwan   in  addition  to  Europe,  the  Americas,  and  Australia  (Hoffman  and  Furcht   2014).  The  future  distribution  of  entrepreneurial  bioscience  will  depend   on  the  forces  of  technological  innovation,  urbanisation,  globalisation,  and   research  investment.  These  forces  are  overcoming  the  historic  inability  of   developing  countries,  many  of  them  in  East  and  South  Asia,  to  adopt  new   technologies  and  employ  them  efficiently  to  achieve  economic  productivity   gains  (Clark  and  Feenstra  2001;  Dabla-­Norris  et  al.  2013).  But  productivity   gains  in  and  of  themselves  are  not  enough.    Achieving  them  through  more   efficient  energy  use  will  be  essential  to  reduce  the  burden  fossil-­fuel   combustion  places  on  natural  biosystems  and  the  environment,  a  burden 6 Asian Biotechnology and Development Review that  pulls  investment  and  energy  away  from  producing  goods  and  services   to  abatement  and  cleanup  activities  and  pollution-­related  health  care   (Laitner  2013).  The  economic  impact  of  Anthropogenic  climate  change,  the   “ecological  bill”  for  the  “Great  Divergence,”  makes  forecasting  economic   growth  increasingly  precarious. Biology  has  been  called  “the  biggest  science,”  with  the  most  scientists,   the  most  funding,  the  most  scientific  results,  the  most  ethical  significance,   and  where  there  is  the  most  to  learn  given  its  billions  of  years  of   experimental  results  involving  self-­replicating  organisms  (Kelly  2006).  The   “bioeconomy”  can  be  understood  as  the  set  of  economic  activities  relating   to  the  invention,  development,  production  and  use  of  biological  products   and  processes  (OECD  2009).  An  emerging  bioeconomy  across  Eurasia  and   around  the  world  will  mark  the  century  ahead.    As  developing  economies   become  wealthier  they  contribute  in  an  ever-­larger  way  “to  pushing  the   technological  frontier  forward,”  say  U.S.  Federal  Reserve  economist  John   Fernald  and  Stanford  University  economist  Charles  Jones.  They  cite  South   Korea  and  China  as  examples  of  countries  showing  more  rapid  growth  in   research  spending  than  the  U.S.,  Europe,  and  Japan  (Fernald  and  Jones   2014).  Some  40  years  ago  China  produced  very  few  PhD’s  in  science  and   engineering;  by  2010  China  was  producing  a  quarter  more  PhD’s  than  the   United  States.  The  fact  that  China  and  India  represent  more  than  one-­third   of  the  world’s  population  prompted  Fernald  and  Jones  to  pose  a  question:     “How  many  future  Thomas  Edisons  and  Steve  Jobses  are  there  in  China   and  India,  waiting  to  realise  their  potential?”   As  the  “Great  Divergence”  was  set  to  commence,  Adam  Smith  wrote  in   The  Wealth  of  Nations  that  China  “has  been  long  one  of  the  richest,  that  is,   one  of  the  most  fertile,  best  cultivated,  most  industrious,  and  most  populous   countries  in  the  world.  It  seems,  however,  to  have  been  long  stationary.”   What  was  true  in  1776  when  Smith  published  his  book  and  for  two  more   centuries  is  no  longer  true.  “In  the  United  States  and  in  the  West,  you  have   a  certain  way,”  Jun  Wang  of  BGI  (formerly  Beijing  Genomics  Institute)  told   Michael  Specter  for  Specter’s  story  “The  Gene  Factory”  about  the  Shenzhen-­ based  genome  sequencing  giant’s  bid  “to  crack  hunger,  illness,  evolution   –  and  the  genetics  of  human  intelligence”  among  other  goals.  “For  the  last   five  hundred  years,  you  have  been  leading  the  way  with  innovation,”  said   Wang,  BGI’s  chief  executive.  “We  are  no  longer  interested  in  following” Divergence, Convergence, and Innovation: East-West Bioscience in an Anxious Age 7 (Specter  2014).  Indeed,  the  center  of  gravity  for  technology  investment   may  well  be  in  the  middle  of  the  Pacific  Ocean,  the  midpoint  between  the   China’s  bustling  east  coast  cities  with  their  numerous  technology  firms  and   the  American  west  coast  with  technology  hubs  running  from  Seattle  to  San   Diego  (Oakley  2015). Innovation  and  Convergence  in  the  Genomic  Exchange  Era Five  hundred  years  ago,  with  China  slipping  from  its  earlier  scientific   pre-­eminence,  the  rapid  rise  of  global  trade  spurred  by  the  spice  trade,   species  exchange,  and  the  introduction  of  novel  food  crops  and  biological   materials  and  fibers  was  a  boon  to  both  urban  development  and  capitalism   in  Europe.  The  Columbian  Exchange  linked  continental  ecosystems   together,  facilitating  the  global  dispersion  of  plants  including  crop  plants,   animals,  insects,  invertebrates,  allergens,  and  infectious  microbes  between   the  Old  World  and  the  New  World  (Crosby  1973).  It  launched  what  some   biologists  consider  the  begin  ning  of  a  new  biological  era:  the  Homogenocene   arising  from  the  homogenising  of  ecosystems  and  loss  of  biodiversity   (Samways  1999).  The  introduction  of  the  potato  to  Europe  from  Peru  may   have  accounted  for  a  quarter  of  the  growth  in  European  population  and   urbanisation  in  the  eighteenth  and  nineteenth  centuries  (Nunn  and  Qian   2011),  easing  ecological  and  population  pressures  and  contributing  to  the   incomes  and  productivity  surge  in  the  West. Today  spices  like  cardamom,  cassia,  cinnamon,  ginger,  nutmeg,  pepper,   and  turmeric  that  spurred  global  trade  in  the  European  “Age  of  Discovery”   are  being  intensively  studied,  particularly  in  India,  for  genomic  markers  to   assist  plant-­breeding  programmes  (IISR  2011).    The  genomes  of  key  crop   plants  in  the  Columbian  Exchange  have  been  fully  or  nearly  sequenced.     They  include  apple,  banana,  barley,  bell  pepper,  cacao  (chocolate),  carrot,   cassava  (manioc),  chili  pepp  er,  cotton,  grape,  maize,  orange,  papaya,  peanut,   pineapple,  potato,  pumpkin,  rice,  rubber,  sorghum,  soybean,  squash,  sugar   beet,  sugarcane,  tomato,  and  wheat  (Hoffman  and  Furcht  2014;  Hoffman   2014).    So  have  many  domestic  ated  animals  in  the  exchange,  including   cat,  chicken,  cow,  dog,  goat,  guinea  pig,  horse,  pig,  sheep,  and  turkey.  The   genomes  of  pathogens  responsible  for  cholera,  malaria,  measles,  smallpox,   typhus,  yellow  fever,  and  other  infectious  diseases  that  devastated  New   World  populations  in  the  post-­Columbian  period  have  also  been  sequenced 8 Asian Biotechnology and Development Review (Hoffman  and  Furcht  2014;  Hoffman  2014).  Meanwhile,  hundreds  of   thousands  of  human  beings  of  vario   us  ethnic  stripes,  infants  included,  have   been  decoded  over  the  past  decade  (Regalado  2014)5,  with  the  number   expected  to  increase  exponentially  as  sequencing  technologies  grow  in   productivity  and  decline  in  price  (Wetterstrand  2015).     In  our  Genomic  Exchange  era,  animal,  plant,  and  microbial  as  well   as  human  genetic  and  regulatory  sequences  travel  around  the  world  over   high-­speed  data  networks.  Genomic  sequence  information  about  crop   plants,  livestock,  natural  materials  and  fibers,  and  pathogens  is  of  great   value  for  agricultural  productivity,  bio-­based  materials  manufacturing,   industrial  bioprocessing,  and  biodiversity  conservation  as  well  as  for  disease   diagnosis,  treatment  and  prevention.  Innovators  can  access  such  information   from  public  sequence  repositor  ies  like  the  National  Institute  of  Health’s   (NIH)  GenBank6,  which  holds  DNA  and  RNA  sequences  from  hundreds   of  thousands  of  species.  China’s  National  Genebank  in  Shenzhen7,  which   BGI  established  and  operates,  aims  to  become  a  comprehensive  collection,   banking,  and  sharing  resource  of  biological  specimens  and  bioinformatics   data  from  humans,  animals,  plants,  and  microorganisms.  BGI  is  also  a   leading  participant  in  the  Earth  Microbiome  Project8,  a  multidisciplinary   effort  to  determine  the  functional  and  evolutionary  diversity  of  microbial   communities  across  the  globe  and  to  produce  a  global  Gene  Atlas. The  Genomic  Exchange  era  has  the  potential  for  creating  new   bioindustries  based  on  the  knowledge  of  life  code  and  how  the  code  builds   and  maintains  proteins,  cells,  and  organisms.  The  practice  of  technological   innovation  in  the  industrial  era  –  the  systematic  application  of  ideas,   inventions  and  technology  to  markets,  trade,  and  social  systems  –  is  now   being  joined  with  the  code  of  life,  DNA,  and  the  basic  unit  of  life,  the   cell.  Data  systems  are  ramping  up  to  handle  the  expected  ‘big  data’  deluge   from  whole  genome  sequencing  and  the  promise  it  holds  for  precise,   individualised  medicine,  personal  health  self-­monitoring  devices  and   apps,  and  next-­generation  drug  development.    The  American  technology   entrepreneur  and  academician  Vivek  Wadhwa  who  studies  how  education,   immigration,  and  entrepreneurship  drive  innovation  makes  a  poignant   observation:  technologies  involving  Micro-­Electro  Mechnical  System   (MEMS)  sensor-­driven  mobile  health  devices,  nanobiology-­based  diagnostic   platforms,  3D  bioprinting,  genomics,  and  DNA  sequencing  and  synthesis Divergence, Convergence, and Innovation: East-West Bioscience in an Anxious Age 9 are  advancing  at  exponential  rates  “even  as  their  prices  fall  and  footprints   shrink”  (Wadhwa  2015).   Innovation  is  poised  to  improve  efficiencies,  lower  costs,  and  spur   entrepreneurial  activity  in  the  $10  trillion  global  healthcare  industry.  In  some   cases,  the  developing  countries  can  innovate  faster  than  developed  countries,   the  so-­called  leapfrog  effect,  because  their  governments  are  actively  working   to  reform  their  health  systems  and  they  face  lower  regulatory  hurdles  (PwC   2015).  Open  innovation  will  serve  as  an  entrepreneurial  accelerator  in  these   efforts  because  the  diffusion  of  knowledge,  the  “public  good  par  excellence”   in  the  words  of  economist  Thomas  Piketty,  is  the  greatest  force  for   technological  convergence  among  nations.  The  Genomic  Exchange  era  will   feature  the  inter-­organisational  sharing  of  anonymised  genetic  and  biological   data,  the  electronic  linking  of  genotypic  and  phenotypic  information  in   medical  records,  and  device-­driven  patient  empowerment  and  public  health.   With  their  promise  of  superior  diagnostics,  targeted  therapies,  and  disease   prevention,  whole  genome  sequencing  and  whole  exome  sequencing  are   beginning  to  transform  health  care  systems,  a  growing  number  of  which   are  building  sequencing  capabilities  in-­house  or  partnering  with  industry.   In  the  West,  Britain  is  proceeding  to  sequence  100,000  genomes  through   its  National  Health  Service  in  partnership  with  Genomics  England.    The   Obama  administration  in  the  U.S.  launched  a  precision  medicine  initiative  in   2015  aimed  at  decoding  the  DNA  of  one  million  volunteers.    The  genomics   entrepreneur  J.  Craig  Venter  and  his  new  company  Human  Longevity,  Inc.   aim  to  sequence  one  million  genomes  by  2020  (Boulton  2015).    In  the  East,   BGI  announced  plans  for  a  “Three  Million  Genomes  Project”  consisting   of  one  million  people,  one  million  microorganisms,  and  one  million  plants   and  animals  (Hardisty  et  al.  2013).    On  a  much  smaller  scale,  Singapore   is  performing  deep  whole  genome  sequencing  of  one  hundred  healthy   Malays,  an  Austronesian  group  that  is  not  represented  in  the  1000  Genomes   catalogue  of  human  genetic  variation  (Wong  et  al.  2013).    Singaporean  and   British  researchers  have  conducted  whole  genome  sequencing  or  whole   exome  sequencing  of  several  hundred  South  Asians  in  search  of  genetic   variants  underlying  susceptibility  to  disorders  such  as  type-­2  diabetes   and  cardiovascular  disease,  which  are  prevalent  in  India  and  constitute  a     growing  burden  on  its  health  care  infrastructure  (Wong  et  al.  2014;   Chambers  et  al.  2014). 10 Asian Biotechnology and Development Review As  technical  barriers  to  human  DNA  sequencing  decrease,  as  sequencing   accuracy  and  depth  grows,  and  as  the  cost  of  whole-­genome  sequencing   approaches  $1000,  whole  genome  and  whole  exome  sequencing  will  be   used  extensively  in  clinical  medicine.  Both  can  aid  clinical  diagnosis,  reveal   the  genetic  basis  of  rare  familial  diseases,  and  inform  disease  biology  and   drug  response  (Dewey  et  al.  2014).    These  technologies  are  also  expected   to  uncover  genetic  findings  of  potential  clinical  importance  in  healthy   individuals  including  infants.  Perhaps  more  than  any  other  sequencing   service,  BGI  is  positioning  itself  to  be  out  front  when  genome  sequencing   takes  hold  in  the  clinic.    Its  sequencing  horsepower,  housed  in  a  former   shoe  factory  in  the  once  sleepy  fishing  village  of  Shenzhen,  has  drawn  the   notice  of  multinational  pharmaceutical  firms  with  which  BGI  has  a  growing   number  of  collaborations.  One  is  the  Asian  Cancer  Research  Group  (ACRG),   jointly  established  by  Lilly,  Merck,  and  Pfizer.  ACRG’s  goal  is  to  build  a   knowledge  bank  of  cancers  common  in  Asia  by  generating  comprehensive   open-­source  genomic  data  sets  to  accelerate  drug  discovery.     BGI  chief  executive  Jun  Wang  revealed  in  early  2015  that  his  sequencing   powerhouse  is  planning  to  gather  and  bank  genomic,  transcriptomic,   epigenomic,  metabolomic  and  microbiomic  data  from  one  million  people,   an  unprecedented  Million  Omics  Database  Project  (Heger  2015).  The   scientific  pre-­eminence  China  once  pos  sessed,  chronicled  by  the  historian,   biochemist,  and  embryologist  Joseph  Needham  in  his  seven-­volume  Science   and  Civilization  in  China,9  has  not  been  forgotten  in  the  Middle  Kingdom. Biomolecules,  Brainpower,  and  the  Shifting  Currents  of   Innovation Commercial  use  of  tools  from  the  revolution  in  molecular  biology   contributed  more  than  $350  billion  to  the  US  economy  in  2012  by  one   estimate,  with  a  10  to  15  per  cent  annual  growth  rate  (Carlson  2014).  If   the  U.S.  experience  is  a  guide  for  future  growth  in  the  field  world  wide,   each  commercial  sector  of  the  biosciences  –  industrial  biotechnology   (including  bioenergy),  genetically  modified  plant  crops,  and  biological  drugs   –  will  contribute  roughly  a  third  to  overall  output.  Products  arising  from   molecular  biology  constitute  a  growing  share  of  the  global  economy  with   each  passing  year  as  technologies  evolve,  production  processes  improve,   and  markets  expand.    In  recent  years  industrial  biotechnology  has  been  the Divergence, Convergence, and Innovation: East-West Bioscience in an Anxious Age 11 fastest  growing  biotechnology  sector  (Carlson  2014).    That  bodes  well  for   mitigation  of  greenhouse  gas  emissions  because  bio-­based  products  in  the   materials  and  chemicals  sectors  (as  well  as  next-­generation  biofuels)  have   a  much  smaller  environmental  footprint  than  products  such  as  petroleum-­ based  plastics  and  petro-­chemicals  (OECD  2011).   Global  investment  in  biotechnology  has  enjoyed  solid  growth  since   2012,  and  2014  was  a  banner  year.  BioCentury’s  Walter  Yang  compared   2014  to  2013  (Yang  2015):     (cid:135)(cid:3) Biotechnology  stock  indices  advanced  at  an  average  of  31  per  cent.   (cid:135)(cid:3) The  industry  raised  nearly  $55  billion  globally,  up  by  47  per  cent.     (cid:135)(cid:3) 112  initial  public  offerings  (IPOs)  raised  a  record  total  of  $9  billion,   up  from  60  IPOs  that  raised  nearly  $4  billion.   (cid:135)(cid:3) The  number  of  IPOs  in  Asia-­Pacific  was  74  compared  to  42;  these   IPOs  raised  $691  million  over  $309  million.     (cid:135)(cid:3) The  private  sector  raised  a  record  $9  billion,  doubling  the  amount   from  2013.  Asia-­Pacific  accounted  for  $274  million  of  private  sector   investment,  up  by  20  per  cent.   Because  of  high  drug  development  costs,  estimated  to  average  $2.5   billion  for  an  approved  prescription  drug  in  the  U.S.  (Mullard  2014),  global   investment  in  the  biotechnology  field  remains  highly  concentrated  in  the   biopharmaceutical  sector.    The  biopharmaceutical  industry,  estimated  to  be  a   $150  -­  $200  billion  global  market10,  was  founded  on  advances  in  molecular   biology  in  the  1970s.  Newer  biological  technologies  like  genomics,  synthetic   biology,  and  regenerative  medicine  are  positioned  where  molecular  biology   was  four  decades  ago,  in  the  early  stages  of  attracting  significant  investment   (Woodford  2015).  Some  of  these  technologies  are  geo-­technologies   involving  automated  bioanalytical  and  biosynthesis  instruments,  systems,   and  devices  often  linked  to  data  networks.11   The  biosciences  have  many  new  cutting-­edge  tools  from  genomics  and   bioinformatics,  cellular  technologies  including  stem  cells,  and  synthetic   biology,  with  assists  from  nanotechnology  and  automation.    These  tools   make  it  possible  to  sequence  and  synthesize  DNA  at  an  industrial  scale,   edit  genes  precisely,  control  the  growth  and  differentiation  of  cells  and   print  them  in  three-­dimensional  constructs  (bioprinting).  They  also  make 12 Asian Biotechnology and Development Review it  possible  to  create  microbial  factories  that  produce  medicines,  renewable   fuels  and  chemicals,  and  biodegradable  materials.       As  noted  above,  growth  in  the  industrial  biotechnology  sector  –  for   cleaner  and  greener  technology,  chemicals,  materials,  and  fuels  –  is  vital   for  severing  the  link  between  economic  growth  and  CO  emissions  (OECD   2 2011;  BIO  2013).  We  are  at  the  dawn  of  the  industrial  enzymes  era  that   is  putting  existing  enzymes  to  novel  uses  and  creating  novel  enzymes  to   catalyse  an  expanding  array  of  biochemical  reactions.  Asia  accounts  for   more  than  one-­third  of  the  multi-­billion  dollar  industrial  enzymes  export   market,  with  China  accounting  for  20  per  cent  (Binod  et  al.  2013).    The   potential  for  synthetic  biology  and  metabolic  engineering  to  accelerate   growth  in  the  design  and  manufacture  of  industrial  enzymes  and  bio-­based   products  is  just  beginning  to  be  realised.     Genetic  networks  and  biosynthetic  pathways  in  microorganisms  are   being  adapted,  reorganised  and  recreated  to  manufacture  biopolymers,   bioacrylics,  butanol,  bio-­isoprene  for  tires,  surfactants,  and  1,3-­propanediol   (PDO),  a  production  platform  for  solvents,  adhesives,  resins,  detergents,  and   cosmetics.  The  integration  of  software  and  wetware  in  synthetic  biology   (synbio)  should  dramatically  shorten  the  innovation  cycle  for  making  new   bio-­based  products  (OECD  2014).  Bioremediation  has  been  employing   microorganisms  to  reduce  heavy  metal  contaminants  in  soil  and  water   for  several  decades  but  with  less  than  optimal  utility.  Synbio  coupled   with  genomics,  biosensing  and  ecosystem  profiling  constitute  potentially   invaluable  tools  for  designing  novel  and  much  more  effective  environmental   remediation  systems  for  soil  and  water  contamination,  a  significant  problem   for  fast-­growing  countries  in  East  and  South  Asia  (Wong    2013;  Banerjee   and  Sanyal  2011).   Genomics  is  opening  a  window  on  genetic  alleles  that  enable  food  crops   including  wheat,  rice,  and  maize  (corn),  Earth’s  major  cereal  crops,  to  adapt   to  a  changing  climate.  Their  yield  needs  to  grow  by  an  estimated  70  per   cent  by  mid-­century  to  feed  the  projected  nine  billion  people  expected  to   then  inhabit  Earth  (Kole  2013).  Much  of  the  overall  population  increase   between  now  and  2050  is  projected  to  take  place  in  high-­fertility  countries,   mainly  in  Africa  but  also  countries  with  large  populations  such  as  India,   Indonesia,  Pakistan,  the  Philippines  and  the  United  States  (UN  2013).  The